NCT02147990 2020-08-12
NSCLC
Clovis Oncology, Inc.
Phase 2 Terminated
Clinical Trials
7 trialsNCT01526928 2020-08-04
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Clovis Oncology, Inc.
Phase 1/2 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT02630186 2019-07-05
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
Clovis Oncology, Inc.
Phase 1/2 Terminated
NCT02580708 2018-10-02
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
Clovis Oncology, Inc.
Phase 1/2 Terminated
NCT02547675 2018-09-25
Rociletinib (CO-1686) USA Expanded Access Program
Clovis Oncology, Inc.
No longer available
NCT02705339 2016-05-17
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
Washington University School of Medicine
Phase 2 Withdrawn